Table 5.

Risk for the outcome stratified by treatment after PS matching analysis

VariablePost–PS Matching Analysis
Logistic RegressionCox Regression
OR (95% CI)P valueIRR (95% CI)P valuea
Remission at 6 mo
 RTX versus CYC1.49 (0.62 to 3.57)0.3771.37 (0.91 to 2.08)0.132
 PLEX versus no PLEX0.61 (0.23 to 1.63)0.3230.73 (0.44 to 1.22)0.230
Relapse at 12 mo
 RTX versus CYC1.81 (0.69 to 4.80)0.2301.61 (0.67 to 3.89)0.289
 PLEX versus no PLEX1.90 (0.51 to 7.09)0.3370.53 (0.16 to 1.82)0.315
Combined events of ESKD and/or death at 18 mo
 RTX versus CYC0.84 (0.37 to 1.91)0.6770.87 (0.42 to 1.78)0.699
 PLEX versus no PLEX1.11 (0.46 to 2.68)0.8221.05 (0.51 to 2.18)0.891
Survival at 24 mo
 RTX versus CYC1.69 (0.52 to 5.46)0.3841.57 (0.51 to 4.80)0.429
 PLEX versus no PLEX0.53 (0.14 to 1.95)0.3400.54 (0.16 to 1.85)0.329
ESKD at 24 mo
 RTX versus CYC0.56 (0.23 to 1.34)0.1910.61 (0.28 to 1.35)0.224
 PLEX versus no PLEX1.11 (0.45 to 2.74)0.8181.06 (0.50 to 2.25)0.887
Combined events of ESKD and/or death at 24 mo
 RTX versus CYC0.72 (0.32 to 1.60)0.4150.77 (0.38 to 1.54)0.452
 PLEX versus no PLEX1.00 (0.42 to 2.40)1.0000.99 (0.48 to 2.02)0.971
  • a P value <0.05 is considered significant.